Premium
Lenalidomide as a second‐line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome
Author(s) -
Kim Hawk,
Lee JeHwan,
Lee WonSik,
Kim Inho,
Moon Joon Ho,
Choi Chul Won,
Lee Ho Sup,
Park Jinny,
Choi Yunsuk,
Shin HoJin,
Cho SuHee,
Kim Kyoung Ha,
Kim SungYong,
Kim YooJin
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15991
Subject(s) - lenalidomide , myelodysplastic syndromes , medicine , hypomethylating agent , oncology , azacitidine , decitabine , bone marrow , multiple myeloma , biology , genetics , gene expression , dna methylation , gene